RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120
Yu, J.-S., Liao, H.-X., Pritchett, J., Bowman, C., Vivian, C., Parks, R., Xia, S.-M., Cooper, M., Williams, W. B., Bonsignori, M., Reed, S. G., Chen, M., Vandergrift, N., Rice, C. M., & Haynes, B. F. (2017). Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. Journal of Virological Methods, 249, 85-93. https://doi.org/10.1016/j.jviromet.2017.08.012
Development of a HIV-1 vaccine is a major global priority. The yellow fever virus (YFV) attenuated vaccine 17D is among the most effective of currently used vaccines. However, the stability of the YFV17D vector when carrying non-flavivirus genes has been problematic. We have constructed and expressed HIV-1 Env in YFV17D with either single transmembrane (STM) or double transmembrane (DTM) YFV E protein domains for the development of anti-HIV antibodies. Here we describe modifications of the YFV17D vector such that HIV-1 Env gp120 is expressed in up to 5 passages in Vero cells. Immunization with recombinant YFV17D vector prime followed by HIV-1 CH505 TF gp120 protein boosts were able to induce neutralizing antibodies for a HIV-1 tier 1 isolate in mice. This modified YFV vector may be a starting point for constructing HIV-1 vaccine candidate priming vectors.
